TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07650084: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chr

Sponsor: GlaxoSmithKline · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 75 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT07650084 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07650084 Rescue Dossier →